BioWorld

Oct. 14, 2003

View Archived Issues

FDA Accepts ImClone's Erbitux Filing, Grants It Priority Review

Read More

Elixir Pharmaceuticals Gets $19M In Second B' Round

Read More

Georgia, Among Others, Seeking To Grow Through Life Sciences

Read More

Xcyte Seeking $75M In Second Attempt At Initial Public Offering

Read More

Other News To Note

Read More

Corgentech, BMS Enter Graft Deal Valued At Up To $250M

With two Phase III trials under way testing its treatment to prevent vein-graft failure after surgery, Corgentech Inc. is joining with Bristol-Myers Squibb Co. in a deal that's expected to get revenue flowing better. (BioWorld Today) Read More